IBRX
Price
$4.95
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
111 days until earnings call
RXRX
Price
$7.58
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
111 days until earnings call
Ad is loading...

IBRX vs RXRX

Header iconIBRX vs RXRX Comparison
Open Charts IBRX vs RXRXBanner chart's image
ImmunityBio
Price$4.95
Change-$0.00 (-0.00%)
Volume$10.31M
CapitalizationN/A
Recursion Pharmaceuticals
Price$7.58
Change-$0.00 (-0.00%)
Volume$6.81M
CapitalizationN/A
IBRX vs RXRX Comparison Chart
Loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
IBRX vs. RXRX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a Buy and RXRX is a StrongSell.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (IBRX: $4.95 vs. RXRX: $7.58)
Brand notoriety: IBRX and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 180% vs. RXRX: 139%
Market capitalization -- IBRX: $3.37B vs. RXRX: $2.1B
IBRX [@Biotechnology] is valued at $3.37B. RXRX’s [@Biotechnology] market capitalization is $2.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than IBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 6 bullish TA indicator(s).

  • IBRX’s TA Score: 3 bullish, 6 bearish.
  • RXRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а -9.01% price change this week, while RXRX (@Biotechnology) price change was +11.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.86%. For the same industry, the average monthly price growth was +5.66%, and the average quarterly price growth was +6.44%.

Reported Earning Dates

IBRX is expected to report earnings on Mar 04, 2025.

RXRX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-1.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($3.37B) has a higher market cap than RXRX($2.1B). IBRX YTD gains are higher at: -1.394 vs. RXRX (-23.124). RXRX has higher annual earnings (EBITDA): -348.35M vs. IBRX (-436.05M). RXRX has more cash in the bank: 474M vs. IBRX (218M). RXRX has less debt than IBRX: RXRX (89.9M) vs IBRX (736M). RXRX has higher revenues than IBRX: RXRX (48.6M) vs IBRX (1.31M).
IBRXRXRXIBRX / RXRX
Capitalization3.37B2.1B161%
EBITDA-436.05M-348.35M125%
Gain YTD-1.394-23.1246%
P/E RatioN/AN/A-
Revenue1.31M48.6M3%
Total Cash218M474M46%
Total Debt736M89.9M819%
FUNDAMENTALS RATINGS
IBRX: Fundamental Ratings
IBRX
OUTLOOK RATING
1..100
81
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
PROFIT vs RISK RATING
1..100
87
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IBRXRXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 17 days ago
87%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 14 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
IBRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NCTWX36.93-0.12
-0.32%
Nicholas II I
CCPCX14.21-0.06
-0.42%
FS Chiron Capital Allocation C
PLVIX21.53-0.16
-0.74%
Principal Large Cap Value III Inst
RNPAX60.57-0.65
-1.06%
American Funds New Perspective R1
DASVX17.33-0.24
-1.37%
Dunham Small Cap Value A

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-9.17%
AXON - IBRX
48%
Loosely correlated
-3.38%
ARRY - IBRX
41%
Loosely correlated
-1.35%
RXRX - IBRX
39%
Loosely correlated
-3.32%
AMRN - IBRX
37%
Loosely correlated
-1.36%
VCYT - IBRX
35%
Loosely correlated
-1.65%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with BEAM. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-3.32%
BEAM - RXRX
62%
Loosely correlated
-7.94%
CRSP - RXRX
57%
Loosely correlated
-7.53%
EXAI - RXRX
55%
Loosely correlated
-2.35%
PRME - RXRX
54%
Loosely correlated
-1.59%
NTLA - RXRX
53%
Loosely correlated
-4.86%
More